Precision Medicine in Oncology® | Specialty

Dr. Gadgeel on the Utility of Liquid Biopsies in Lung Cancer

January 31st 2020

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the utility of liquid biopsies in lung cancer.

Dr. Gutierrez on the Safety Profile of Pembrolizumab-Based Combos in NSCLC

January 31st 2020

Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).

Dr. Ciombor on the Goals of the COLOMATE Trial in mCRC

January 31st 2020

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

PD-L1: A Biomarker With Baggage

January 30th 2020

Although PD-L1 expression is the most established yardstick of response to immune checkpoint immunotherapy, its clinical utility as a biomarker remains an enigma further complicated by the variety of assays and algorithms for measuring it.

Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung Cancer

January 30th 2020

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

Dr. Randall of Tumor Sequencing Research in Sarcomas

January 30th 2020

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Dr. Hudson on the Rise of Liquid Biopsies in Lung Cancer

January 30th 2020

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Dr. Polsky on the Exploration of Blood-Based Biomarkers in Melanoma

January 30th 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Dr. Martin on Biomarker-Driven Therapeutics in Multiple Myeloma

January 29th 2020

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

January 29th 2020

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor

January 29th 2020

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

CMS Expands Coverage of NGS Diagnostic Tests for Germline Ovarian, Breast Cancers

January 29th 2020

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Gene Signatures Predict for Radiation Response in Breast Cancer

January 28th 2020

Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.

2019 ASH; Best Abstracts for CLL

January 28th 2020

CAR T-Cell Therapy for Relapsed/Refractory CLL

January 28th 2020

Sequencing Strategies for CLL

January 28th 2020

PI3 Kinase Inhibitors for Relapsed/Refractory CLL

January 28th 2020

Management of CLL Progression After Ibrutinib

January 28th 2020

Resistance to Therapy in CLL

January 28th 2020

Combinations for Relapsed or Refractory CLL

January 28th 2020